Behçet’s disease in children: single-center experience
Çocuklarda Behçet hastalığı: tek merkez deneyimi

© Murat Soner Çirkinoğlu, Selcan Demir, Yelda Bilginer, Seza Özen

1Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey
2Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey

Cite this article as: Çirkinoğlu MS, Demir S, Bilginer Y, Özen S. Behçet’s disease in children: single-center experience. Turk Pediatri Ars 2019; 54(3): 179–84.

Abstract
Aim: In this study, it was aimed to summarize the demographics, and clinical and laboratory findings of children who were diagnosed as having Behçet’s disease, and also to determine the efficacy, duration, and adverse effects of the treatments.

Material and Methods: The records of 34 patients who were diagnosed according to the International Behçet Study Group criteria between 1980 and 2013 in the Department of Pediatric Nephrology and Rheumatology, Hacettepe University Faculty of Medicine, were retrospectively reviewed and all demographic and clinical features were recorded. In the light of these data, the sex and age distribution, clinical and laboratory findings, most commonly preferred treatment approaches, efficacy of treatments, and adverse effects during treatment were analyzed.

Results: Of the 34 children with Behçet’s disease, 18 (53%) were male and 16 (47%) were female, and the mean age was 11.88±3.34 years. There was no significant difference in age distribution of the male and female patients (p>0.05). In 97% (n=33) of the patients, the first symptom was recurrent oral aphthae. In order of frequency, the other mucocutaneous findings were pseudofolliculitis and pustular lesions (82%), genital ulcers (62%), and pathergy positivity (50%). System involvements in order of frequency were as follows: joint findings (38%), ocular findings (35%), vascular involvement (32%), neurologic involvement (18%), gastrointestinal involvement (5.8%), and pulmonary involvement (5.8%). Colchicine was the most commonly preferred drug (88%). Steroids were added to treatment in patients with skin involvement. Azathioprine was added in patients with uveitis. Anticoagulant therapy, cyclophosphamide, and anti-tumor necrosis factor-alpha were added in patients with vascular involvement. In patients with gastrointestinal system involvement, sulfasalazine was added to treatment. Diarrhea was the most common adverse effect in patients who used colchicine. In the patients who used steroid treatment, gastrointestinal symptoms such as unintentional weight gain, acne, and agitation were observed (17%). One patient who received interferon treatment had symptoms of depression and agitation.

Conclusion: The aim of this study was to review the general characteristics of pediatric patients with Behçet’s disease and to emphasize the importance of early diagnosis and correct treatment in terms of mortality and morbidity.

Keywords: Behçet’s syndrome, HLA-B51, pediatrics

ÖZ
Amaç: Bu çalışmada Behçet hastalığı tanıısı almiş çocuk hastaların demografik, klinik ve laboratuvar bulgularının özelliklerini, uygunlanan tedavilerin etkinliği, etki süresi ve karşılaşılan yan etkilerin belirlenmesi amaçlanmıştır.

Gereç ve Yöntemler: Hacettepe Üniversitesi Tıp Fakültesi Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Çocuk Nefroloji ve Romatoloji Bilim Dalı’nın 1980–2013 yılları arasında Uluşlararası Behçet Çalışma Grubu ölçütlerine göre tanı almış hastaların arşivi incelenerek toplam demografik ve klinik özellikleri kaydedildi. Veri analizinde çocuklu Behçet hastalarının genel özellikleri gözden geçirilmiştir, erken tanı ve tedavinin önemi vurgulanmıştır.

Bulgular: Otuz dört çocuk Behçet hastasının 18’si (%53) erkek ve 16’sı (%47) kızdi ve yaş ortalaması 11,88±3,34’tü. Kız ve erkek hastaların yaş dağılımalarda anlamlı fark yoktu (p>0,05). Hastaların %97’sinde (n=33) ilk başvuru yakınına fark tekrarlı orantı oral altı was. Sıklık sırasına göre diğer mukokutanöz bulgular; psödofolikülit ve püštüler lezyonlar (%62) genital ulser (%62), paterji pozitifiği (%60) idi. Sistem tutulumları ise slikk présansına göre; eklem bulguları (%638), göz bulguları (%635), vasküller tutulum (%632), nörolojik tutulum (%6318), gastrointestinal tutulum (%65,8) ve akciğer tutulumu (%65,8) oranda sahaptı. Kolşisın en çok tercih edilen ilaçlı (%688). Cilt tutulumu olan oğularda tedaviye steroid, üveit oğulardan azatiopürin, vasküler tutulumda antiakoagülan tedavide birlikte sikiťlosfamid ve anti-tümör nekrozis faktör (TNF)-alfa, gastrointestinal sistem tutulumu oğularda sulfaşalazin tedavide eklenmiştir. Kolşisin kullanılar halata da en sık rastlanan oğulun en etki ishaldı. Steroid kullanım halatasında gastrointestinal sistem yakınmaların, istemsiz kıl alımı, akın ve ajıtasıyan yakınmaların (%17) gözlemlenmişti. Interferon tedavisi alan bir haste depresyona ve ajıtasıyan yakınma

Anahtar sözcükler: Behçet hastalığı, çocuk, HLA-B51
**Introduction**

Behçet’s disease (BD) is an autoimmune disease that may involve many organ systems including the central nervous system, musculoskeletal system, and gastrointestinal system, and it is characterized by ocular and cutaneous findings, as well as recurring oral and genital ulcers. The Turkish dermatologist Hulusi Behçet first described the disease in 1937, as the triad of recurrent oral aphthous ulcers, genital ulcers, and uveitis (1). Subsequently, superficial thrombophlebitis was added to these findings in 1946 (2).

In a recent multi-center study, 219 patients were examined prospectively, and it was emphasized that at least three of these criteria should be present for a diagnosis of pediatric BD: recurrent oral aphthous ulcers (at least three attacks per year), genital ulcers, skin involvement, eye involvement, neurologic involvement, and vascular involvement. Skin involvement is considered as necrotic folliculitis, acneiform lesions or erythema nodosum, whereas venous thrombosis, arterial thrombosis, and arterial aneurisms are regarded as vascular involvement (3). Behçet’s disease is commonly observed in the region of the Silk Road, which also includes our country.

In our study, we aimed to evaluate the demographics, and clinical and laboratory characteristics of children who were followed up with a diagnosis of BD. We aimed to enlighten the approach to childhood BD by evaluating treatment efficacies and durations, as well as adverse effects and long-term follow-up data.

**Material and Methods**

Thirty-four patients who were followed up with a diagnosis of BD in Hacettepe University, Faculty of Medicine, Division of Pediatric Nephrology and Rheumatology between 1980 and 2013, were included in the study. The patient files and electronic records were examined retrospectively. According to the International Study group criteria, the presence of at least two of the following findings was considered as Behçet’s disease: recurring oral aphthous ulcers (at least three times per year), genital ulcers, ophthalmologic findings, cutaneous findings, and a positive pathergy test (4, 5). The patients’ demographic characteristics, ages at the time of diagnosis, findings at first presentation, pathergy tests, human leucocyte antigen (HLA)-5 and B51 positivity, family history, treatment after the diagnosis and treatment responses, complications related to medications and other complications were evaluated. In our study, the HLA-B51 concentrations were also examined because it was emphasized that this marker showed the strongest correlation with BD in a study in which studies related to childhood vasculitis were evaluated (6).

Changes in clinical findings can be evaluated using the Behçet Disease Current Activity Form (BDCAF). Common findings of BD are interrogated at clinical visits with this form (7). At each clinical visit, the patients were asked about the clinical findings that they thought they had, and the changes in these findings. In addition, physicians’ observations were noted in their files according to the BDCAF criteria. Improvement in the laboratory findings was considered as treatment response. Currently, the tests used most commonly for the assessment of laboratory findings include the erythrocyte sedimentation rate (ESR) and C-reactive protein concentrations, and an approach of these values to normal values at the next visit is considered improvement in laboratory findings. The study was conducted in accordance with the principles of the Declaration of Helsinki. Ethics committee approval was obtained on August 1st, 2014, from Hacettepe University Non-interventional Clinical Research Ethics Committee (Project No.: LUT GO 14/12).

**Statistical Analysis**

The Statistical Package for the Social Sciences (SPSS) software was used for analysis of the data. The relationship between the variables and the normality of distribution was examined using analytical methods (Kolmogorov-Smirnov/Shapiro-Wilk tests). Median and minimum-maximum values were used for descriptive data. The Mann-Whitney U test was used for the comparison of continuous variables between the groups, and the Chi-square or Fisher’s test were used for the comparison of percentages because the values observed in cells did not meet Chi-square test assumptions. A p value of <0.05 was considered significant.

**Results**

**The patients’ general characteristics**

Sixteen (47%) of the 34 patients who were included in the study were female and 18 (53%) were male. The mean age was 16.55±4.11 years. The mean age at the time of first presentation was 11.18±3.34 years. No significant difference was found in the age distribution of the female and male patients (p<0.05). Third-degree consanguinity was present in the parents of one patient. There was no consanguinity between the parents of the other patients. Fifteen percent of the patients (n=5) had a family member with Behçet’s disease. Six patients (18%) had relatives with rheumatic disease other than BD. The pathergy test was positive in half of the patients (n=17). HLA-B51 was positive in five of 10 patients in whom HLA-B51 concentrations were measured.

**The patients’ symptoms and findings at the first presentation**

The most common symptom at the time of presenta-
Adverse effects that are thought to be associated with treatment
The most common adverse effect was diarrhea in the patients who used colchicine. Gastrointestinal system symptoms, unintentional weight gain, acne, and agitation were observed in the patients who used steroid treatment (17%). Depression and agitation occurred in one patient who received interferon treatment.

Discussion
Early diagnosis and treatment is considerably important in BD to prevent the development of complications because it is a chronic and multi-system disease. In this study, the clinical findings and treatment approaches in 34 patients who were being followed up with a diagnosis of BD were cited. In our study, the mean age at the first presentation was found to be 11.18±3.34 years. This was similar to the finding reported as 12.3 years in a multi-center study conducted by Karıncaoğlu et al. (8) in which 83 pediatric patients with BD were evaluated. The male/female ratio was reported as 33/32 in an international multi-center demographic study conducted by Kone-Paut et al. (9). This ratio was found as 18/16 in our study; no significant difference was found in terms of sex distribution (1,12/1).

In previous studies, oral aphthous ulcers were reported in 100% of the cases and genital ulcers were reported in 98.7% of cases (10). In our study, recurring oral aphthous ulcers were the most common cause for presentation in 97% of patients. In the study conducted by Kim et al. (11), cutaneous lesions other than oral and genital ulcers were reported with a rate of 27%. In contrast to the literature, the second most common cause for presentation in our patients was other cutaneous lesions (82%). Genital ulcers were found with a lower rate compared with other studies (62%). In a multi-center study conducted with 110 pediatric patients with BD in Italy, the second most common clinical finding was reported to be ophthalmologic involvement rather than genital ulcers (12). This suggests that the second most common findings show differences from country to country, though the most common clinical finding was oral aphthous ulcers.

Although it is accepted that a positive pathergy test has a high sensitivity and specificity in the diagnosis of BD, recent studies have reported that this tendency has de-
increased (13). Studies have reported positive pathergy tests with a rate of 40–50% (14). In our study group, this rate was found as 34% (n=17).

Currently, HLA-B51 is considered as the strongest genetic risk factor for BD (15). Although HLA-B51 positivity is found with a rate of 20% in healthy individuals, this rate may increase up to 50–80% in patients with BD (16). In our study, HLA-B51 was found to be positive in five (50%) of 10 patients in whom HLA-B51 was tested.

In BD, the most common ophthalmologic complication is uveitis, which is bilateral in 75% of the cases. In addition, panuveitis was reported with a rate of 54%, posterior uveitis was reported with a rate of 29%, and anterior uveitis was reported with a rate of 17% when uveitis related to BD was classified (9). Similar to the literature, panuveitis was also found most commonly (67%) in our study; posterior uveitis was found with a rate of 25% and anterior uveitis was found with a rate of 8%. Posterior uveitis is a serious condition and is frequently treated with immunosuppressive agents including azathioprine and cyclosporine, and with corticosteroids (17, 18). In addition, interferon is very effective in severe cases of uveitis and preferred in many centers (19). In our patients with uveitis, steroid and azathioprine were preferred frequently. Among the patients who did not respond to treatment, treatment was substituted with cyclosporine A in four patients, with anti-TNF in two patients and with interferon in five patients. All cases of uveitis were successfully treated.

In other studies, the frequencies of neurologic and vascular involvement have been reported to be 15% (9). In our study, vascular involvement was found in 32% of patients, and neurologic involvement was found in 18% of the patients.

Yazıcı et al. (20) emphasized that BD had a more severe prognosis in young men in a study they conducted in 2001. The finding that pulmonary aneurism, which was considered to have the highest morbidity and mortality rate, was found in two boys in our study resembled this study. There are insufficient reports related to the correlation of age with disease prognosis in children.

There are no definite recommendations for the treatment of pediatric patients; basically, adult treatment guidelines are used. The drugs to be preferred primarily should be topical sucralfate or corticosteroids in the treatment of oral and genital ulcers (21). Colchicine was found to decrease the frequency of ulcers (22). In our study, colchicine and topical steroids were the most commonly used drugs in the treatment of patients who had oral and genital ulcers, and treatment was occasionally supported with short-term oral steroids. The frequency of oral and genital ulcers was reduced approximately three months after colchicine treatment was initiated. In patients who were resistant to treatment, a marked response was obtained approximately one month after oral steroid treatment was added to treatment. The most commonly preferred drug was colchicine, being recommended in 94% of the patients. However, two patients refused colchicine treatment considering the adverse effects. When describing the drug-related adverse effects that could develop, the family’s concerns should be considered and it should definitely be emphasized that use of the drug could lead to some adverse effects, but the gain and loss balance should be adjusted adequately. The most common symptom related to colchicine is abdominal pain and diarrhea. Seventeen percent of patients (n=5) reported that they had drug-related diarrhea at least once during the time when they used colchicine. Oral steroids were used for approximately three months. The most common steroid-related adverse effect was GIS symptoms and weight gain, and symptoms including acne and agitation also occurred in some patients. Gastro-protective antacid and anti-reflux treatments should be recommended to avoid steroid-related adverse effects.

Vascular involvement developed in 32% of the patients. In the BD Treatment Recommendations Guideline published by Hatemi et al. (22), there is no definite consensus about the use of anticoagulants in vascular involvement. In our series, the patients who had vascular involvement, but did not have pulmonary involvement, were treated with heparin infusion or subcutaneous enoxaparin and warfarin.

Pulmonary artery aneurism was found in two of our patients and they were treated with cyclophosphamide in addition to high-dose IV and oral steroid treatment. In one of these patients, thrombus developed in the IVC and Budd–Chiari syndrome was found in the advanced period; TNF was added to treatment.

In this study, in which the general characteristics of childhood BD were examined, no patient died and the morbidity was found to be at an acceptable level. We think that this finding was caused by the early approach to the disease and careful treatment planning. Multi-center studies are needed both at the time of diagnosis and in the follow-up and treatment.

Some limitations of these studies should be considered. The fact that some tests for HLA-B51 concentrations could not be performed in all patients, and there was a limited number of patients may be considered as limitations. In addition, the fact that the patients were verbally asked about clinical findings and present findings
were noted in patient files rather than using a prepared form for the BDCAF should be considered as a limitation. Also, the study included a pediatric patient group from between 1980 and 2013 and innovations in treatment approaches occurred during this period; therefore, old and new approaches were compared, which should also be considered as a limitation.

Acknowledgement: We would like to show our gratitude to Mine Özdíl Çirkinoğlu from Balıkesir Atatürk City Hospital, for sharing her wisdom with us during the course of this research, and we are also immensely grateful for her comments and contributions on an earlier version of the manuscript.

Ethics Committee Approval: This study was approved by Hacettepe University Non-Interventional Clinical Studies Ethics Board On 08.01.2014 (Approval number: LUT GO 14/12).

Informed Consent: Written consent was not obtained from the patients’ parents because all patients included in the study were evaluated retrospectively.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept - S.Ö., M.S.Ç.; Design - S.Ö., M.S.Ç.; Supervision - S.Ö., M.S.Ç.; Funding - S.Ö., Y.B.; Materials - M.S.Ç., S.Ç.; Data Collection and/or Processing - M.S.Ç., S.D.; Analysis and/or Interpretation - Y.B., S.D.; Literature Review - M.S.Ç., Y.B.; Writing - M.S.Ç., S.Ç.; Critical Review - S.Ö., M.S.Ç.; Other - M.S.Ç., S.D.

Conflict of Interest: The authors have no conflicts of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

References
1. Behçet H. Über rezidiverende Aphthöse, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien.[Article in German] Dermatol Wochenschr 1937; 105: 1151–7.
2. Adamantiades B. Le thrombophlebite comme quatrième symptom de l’iritis recidivante a hypopyon. Ann Ocul 1946; 179: 143-8.
3. Kone-Paut I, Shahram F, Darce-Bello M, et al; PEDBD Study Group for Behçet’s Disease. Consensus classification criteria for paediatric Behçet’s disease from a prospective observational cohort: PEDBD. Ann Rheum Dis 2016; 75: 958–64. [CrossRef]
4. Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet 1990; 335: 1078–80.
5. Evaluation of diagnostic ‘(classification)’ criteria in Behçet’s disease--towards internationally agreed criteria. International Study Group for Behçet’s disease. Br J Rheumatol 1992; 31: 299–308. [CrossRef]
6. Ozen S, Acar-Ozen NP. Recent advances in childhood vasculitis. Curr Opin Rheumatol 2017; 29: 530–4. [CrossRef]
7. Zayed HS, Medhat BM, Seif EM. Evaluation of treatment adherence in patients with Behçet’s disease: its relation to disease manifestations, patients’ beliefs about medications, and quality of life. Clin Rheumatol 2019; 38: 761–8.
8. Karincaoglu Y, Borlu M, Toker SC, et al. Demographic and clinical properties of juvenile-onset Behçet’s disease: a controlled multicenter study. J Am Acad Dermatol 2008; 58: 579–84. [CrossRef]
9. Koné-Paut I, Yurdakul S, Bahabri SA, et al. Epidemiological features of Behçet’s syndrome in children: an international collaborative survey of 86 cases. J Pediatr 1998; 132: 721–5. [CrossRef]
10. Kilian NC, Sawalha AH. Behçet’s disease in the United States: A single center descriptive and comparative study. Eur J Rheumatol 2017; 4: 239–44. [CrossRef]
11. Kim DK, Chang SN, Bang D, et al. Clinical analysis of 40 cases of childhood-onset Behçet’s disease. Pediatr Dermatol 1994; 11: 95–101. [CrossRef]
12. Gallizzi R, Pidone C, Cantarini L, et al. A national cohort study on pediatric Behçet’s disease: cross-sectional data from an Italian registry. Pediatr Rheumatol Online J 2017; 15: 84. [CrossRef]
13. Alpsoy E. Behçet’s disease: A comprehensive review with a focus on epidemiology, etiology and clinical features,
and management of mucocutaneous lesions. J Dermatol 2016; 43: 620–32. [CrossRef]

14. Kaklamani VG, Vaiopoulos G, Kaklamani PG. Behçet’s disease. Semin Arthritis Rheum 1998; 27: 197–217.

15. Hatemi G, Seyahi E, Fresko I, Talarico R, Hamuryudan V. One year in review 2017: Behçet’s syndrome. Clin Exp Rheumatol 2017; 108: 3–15.

16. Sano K, Yakubi K, Imagawa Y, et al. The absence of disease-specific polymorphisms within the HLA B51 gene that is the susceptible locus for Behçet’s disease. Tissue antigens 2001; 58: 77–82. [CrossRef]

17. Ozdal PC, Ortac S, Taskintuna I, Firat E. Long-term therapy with low dose cyclosporin A in ocular Behcet’s disease. Doc Ophthalmol 2002; 105: 301–12. [CrossRef]

18. Yazıcı H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 1990; 322: 281–5. [CrossRef]

19. Albayrak O, Oray M, Can F, et al. Effect of Interferon alfa-2a Treatment on Adaptive and Innate Immune Systems in Patients With Behçet Disease Uveitis. Invest Ophthalmol Vis Sci 2019; 60: 52–63. [CrossRef]

20. Yazıcı H, Yurdakul S, Hamuryudan V. Behçet’s syndrome. Curr Opin Rheumatol 2001; 13: 18–22. [CrossRef]

21. Ozen S. The spectrum of vasculitis in children. Best Pract Res Clin Rheumatol 2002; 16: 411–25. [CrossRef]

22. Hatemi G, Silman AD. Bang, et al; EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656–62.